



- (51) **International Patent Classification:**
C07K 14/11 (2006.01) *A61K 39/145* (2006.01)
- (21) **International Application Number:**
PCT/US2024/055819
- (22) **International Filing Date:**
14 November 2024 (14.11.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/599,361 15 November 2023 (15.11.2023) US
- (71) **Applicant:** **RED QUEEN THERAPEUTICS, INC.**
[US/US]; 245 Main St., Floor 12, Cambridge, Massachusetts 02142 (US).
- (72) **Inventors:** **HERCE, Henry David**; c/o Red Queen Therapeutics, Inc., 245 Main St., Floor 12, Cambridge, Massachusetts 02142 (US). **DASILVA-JARDINE, Paul**; c/o Red Queen Therapeutics, Inc., 245 Main St., Floor 12, Cambridge, Massachusetts 02142 (US). **VASH, Brian Edward**; c/o Red Queen Therapeutics, Inc., 245 Main St., Floor 12, Cambridge, Massachusetts 02142 (US).

- (74) **Agent:** **D'AMATO, Erica M.** et al.; Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** ANTIVIRAL STRUCTURALLY STAPLED INFLUENZA PEPTIDES AND USES THEREOF

		Therapeutic Peptide															
		77	79	81	83	85	87	89	91	93	95	97	99	101	103	105	107
Subtype	Sequences	76	78	80	82	84	86	88	90	92	94	96	98	100	102	104	106
H1N1	6264	R	I	E	N	L	N	K	K	V	D	G	F	L	D	I	W
H1N2	42	R	M	E	N	L	N	K	K	V	D	G	F	L	D	I	W
H2N2	102	R	L	E	N	L	N	K	K	V	D	G	F	L	D	I	W
H3N2	9021	R	I	Q	D	L	E	K	V	E	D	T	K	I	D	L	W
H5N1	439	R	I	E	N	L	N	K	K	V	D	G	F	L	D	I	W
H7N9	89	Q	I	G	N	V	I	N	W	T	R	D	S	I	T	E	V




FIG. 1

(57) **Abstract:** The present disclosure provides structurally stapled peptides useful for the treatment and/or prevention of an influenza infection, as well as methods of treating and/or preventing an influenza infection.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*